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Abstract
Objective—The objective of this study was to evaluate the feasibility and outcomes of 
incorporating value of information (VOI) analysis into a stakeholder-driven research prioritization 
process in a US-based setting.
Methods—Within a program to prioritize comparative effectiveness research areas in cancer 
genomics, over a period of 7 months, we developed decision-analytic models and calculated 
upper-bound VOI estimates for three previously selected genomic tests. Thirteen stakeholders 
representing patient advocates, payers, test developers, regulators, policy-makers, and community-
based oncologists ranked the tests before and after receiving VOI results. The stakeholders were 
surveyed about the usefulness and impact of the VOI findings.
Results—The estimated upper-bound VOI ranged from $33M to $2.8 billion for the three 
research areas. Seven stakeholders indicated the results modified their rankings, nine stated VOI 
data was useful, and all indicated they would support its use in future prioritization processes. 
Some stakeholders indicated expected value of sampled information might be the preferred choice 
when evaluating specific study designs.
Limitations—Our study was limited by the size and the potential for selection bias in the 
composition of the external stakeholder group, lack of a randomized design to assess effect of VOI 
data on rankings, and the use of expected value of perfect information versus expected value of 
sample information methods.
Conclusions—Value of information analyses may have a meaningful role in research topic 
prioritization for comparative effectiveness research in the US, particularly when large differences 
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in VOI across topic areas are identified. Additional research is needed to facilitate the use of more 
complex value of information analyses in this setting.
Introduction
In a healthcare system with limited resources for research, it is vital to identify research 
areas with the greatest likelihood of influencing clinical practice and improving patient 
outcomes. A quantitative approach to research prioritization that has received increased 
attention, particularly within the context of comparative effectiveness research, is value of 
information (VOI) analysis. This approach involves the application of methods from 
economic theory and decision analysis to estimate the humanistic and economic value of 
performing additional research to better understand the safety, efficacy, and cost of 
technologies and medical interventions.(1, 2)
The VOI approach, though conceptually compelling, is complex and can be nontransparent 
to decision makers. A multitude of stand-alone VOI analyses have been published 
evaluating a diverse range of research topics, but VOI has rarely been used to inform 
research funding decisions. In the UK, two pilot VOI research prioritization projects have 
been performed with positive results. In the US, a group from Duke university performed a 
pilot study evaluating the potential use of VOI for research prioritization, but no applications 
of VOI directly linked to research decision making processes have been published in the US.
(3–5)
The objective of this pilot study was to assess the feasibility, strengths, and weaknesses of a 
pragmatic approach for incorporating formal VOI analysis into a stakeholder-driven 
research prioritization process. This study was conducted within the context of the Center 
for Comparative Effectiveness Research in Cancer Genomics (CANCERGEN), a 
collaboration between four institutions: Fred Hutchinson Cancer Research Center, the 
SWOG (Southwest Oncology Group), one of the largest cancer clinical trials groups in the 
US, the University of Washington, and the Center for Medical Technology and Policy.(6) 
The nature of our endeavor was exploratory, and was performed with the aim of informing 
future efforts to integrate VOI into research prioritization.
Methods Overview
Setting
The VOI analyses were conducted to provide external input to SWOG leadership regarding 
priority comparative effectiveness research opportunities in cancer genomics. The approach 
described herein was thus not an evaluation of specific studies or study designs (e.g., RCTs), 
but the first step in quantitatively identifying promising research areas. Integral to the 
process was an external stakeholder advisory group (ESAG) with 13 representatives from a 
diverse range of constituencies: patient advocates (2), payers (3), test developers (2), 
regulators (1), policy-makers (2) and practicing oncologists (3), as previously described.(7) 
These members were chosen based on their knowledge, experience, and willingness to 
commit for a two-year term on the ESAG. The goals were to 1) identify and transmit priority 
research areas to SWOG leadership and investigators for their consideration within existing 
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prioritization processes, and 2) identify topic areas for development of specific comparative 
effectiveness research studies in collaboration with SWOG investigators.
Qualitative Prioritization Process
The qualitative research prioritization process employed within CANCERGEN used a 
structured landscape analysis and ranking by stakeholders using specific criteria to cull the 
many genomic tests in development into a manageable set of three high priority cancer 
genomic tests for further detailed evaluation using VOI.(8) The qualitative criteria used 
were: population impact; adequacy of current standard of care; test performance (i.e. 
analytic and clinical validity); benefits; harms; economic impacts; evidence of need for an 
RCT; clinical trial implementation and feasibility; and market factors. The investigators and 
external advisory group jointly developed these criteria.
The three high priority genomic test topics selected using the qualitative criteria were: 1) 
ERCC1 expression testing for platinum-based adjuvant therapy in fully-resected early-stage 
non-small cell lung cancer (NSCLC), 2) epidermal growth factor receptor (EGFR) mutation 
testing for erlotinib maintenance therapy after 1st line chemotherapy in advanced NSCLC, 
and 3) breast cancer tumor markers (carcinoembryonic antigen and cancer antigens 15-3 and 
27.29) for detection of recurrence after primary breast cancer therapy.
VOI-informed prioritization process
The quantitative VOI prioritization and evaluation process included multiple phases (see 
Figure 1): 1) development of decision-analytic models in collaboration with stakeholders 2) 
calculation of VOI results, 3) education of stakeholders about VOI, 4) presenting and 
discussing the VOI results followed by a re-ranking of tests, and 5) evaluating the 
stakeholders’ perceptions of the VOI analyses on the research prioritization process.
1. Development of models—We used a simulation model approach to estimate the value 
of future research. The decision-analytic models, built in Microsoft excel (Microsoft 
Corporation. Redmond, WA), were designed to reflect key events in the clinical pathway 
between the use of tests and health outcomes and were structured similar to previous models 
we have developed in this area.(9, 10) As part of model development, the ESAG and 
internal modeling experts were provided an opportunity to review model structures, key 
assumptions, and key inputs during a web-enabled conference call. We evaluated internal 
validity by subjecting the model to thorough debugging using null and extreme input values 
and a detailed review of all mathematical formulas and coding. Model schematics, key 
model inputs, and assumptions used to generate VOI results are provided in a technical 
appendix (see Appendix A). Data to populate the models were derived from the literature 
based on systematic searches, expert clinical input, and clinical trial proposals. We 
performed two separate VOI analyses for ERCC1 testing because standard care varies 
between stage I and stage II patients.
2. VOI calculations—We chose a metric called the expected value of perfect information 
(EVPI), which estimates the upper level dollar value of reducing all uncertainty about which 
strategy is the optimal intervention. We chose this measure because it has been used in 
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previous research prioritization exercises outside the U.S. and is not heavily dependent on 
study design considerations, which can vary widely in terms of their structure (e.g. 
prospective vs. retrospective), comparators, and choice of outcomes. The limitations of 
using EVPI as a metric are addressed in the Discussion section. We used the models to 
calculate the net-benefit for a given treatment strategy based on an estimation of the societal 
willingness-to-pay for health gains (e.g., a quality-adjusted life-year, QALY), which allows 
for the conversion of the estimated clinical impact of a given strategy into a monetary value. 
The net-benefit of a given strategy was calculated by subtracting the cost of the strategy 
from the monetized health gains to provide the net-benefit (QALY x willingness to pay – 
cost). We examined a range of willingness to pay thresholds, but for presentation of the 
results to the ESAG, we chose a value of $150,000/QALY as it approximates the revealed 
willingness-to-pay threshold in the U.S.(11)
We performed probabilistic sensitivity analyses using standard methods to calculate the 
probability and consequences (i.e. impact on expected net benefit) of making a wrong 
decision about the treatment decision—which allow the estimation of the upper level per 
patient VOI.(12) Without available data on the correlation of the uncertainty distributions 
we assumed that they were uncorrelated. To generate the upper level population VOI, we 
multiplied the per-patient VOI by the affected population, i.e. the number of patients 
expected to encounter the treatment decision over the lifetime of the technology. The size of 
the affected population was calculated using SEER incidence data, a discount rate of 3%, 
and an assumed 10-year lifetime for the technologies chosen to reflect an approximate 
middle point to the length of time a new technology takes to become fully diffused.(13)
3. Stakeholder education—We prepared and provided the ESAG brief educational 
materials on VOI theory and methodologies as well as technical briefs on the decision 
models that enable the VOI calculations (see Appendices A and B). The education process 
included presentation of the VOI background and model-specific briefs via a moderated 
web-enabled teleconference with the ESAG. The ESAG was provided ample opportunity to 
discuss and ask clarifying questions about VOI and the specific models. In addition, 
electronic versions of the briefing documents were provided for review prior to the 
teleconference.
4. Presentation of VOI results and re-ranking of tests—We presented the results of 
the VOI analyses to the ESAG during a moderated web-enabled teleconference. 
Opportunities were provided for questions and discussion of the findings amongst the ESAG 
members and the CANCERGEN investigators. ESAG members were then asked to re-rank 
the top three tests. The scoring process involved sequential ranking of tests with the top 
choice removed after each round.
5. Stakeholder evaluation of VOI—ESAG members received an online survey to 
evaluate the VOI process consisting of 15 multiple choice, yes/no, and Likert-scale 
questions (see Table 1). Topics included the usefulness of VOI, whether the VOI results 
impacted stakeholders’ ranking, and whether they would like to use VOI in future research 
prioritization exercises. The survey was sent to ESAG members immediately following the 
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presentation and discussion of the VOI results in the initial teleconference and a subsequent 
follow-up call with two stakeholders unable to attend the first call.
Results
After identifying the three top candidate genomic tests it took seven researchers (averaging 
40% full-time equivalent) approximately 7 months to develop the VOI models, educate the 
ESAG about VOI, present and discuss the VOI results, and have the ESAG revote as to their 
top three tests. The estimated cost for this effort was approximately $250,000. The bulk of 
this time was spent developing the decision analytic models and conducting the VOI 
analyses.
VOR Results
The upper-bound VOI for ERCC1 was $2.2 and $2.8 billion in Stage I and Stage II disease, 
respectively; $2.1 billion for BC (breast cancer) markers; and $33 million for EGFR (Table 
2). The affected populations over a ten-year time horizon were estimated to be 234,051 for 
ERCC1 for both stage I and stage II, 416,746 for BC markers, and 170,253 for EGFR. These 
large numbers reflect the high incidence of breast and lung cancers. The probabilities of 
making a wrong decision about testing using existing information for ERCC1 were 26% 
(Stage I lung cancer) and 42% (Stage II lung cancer), 43% for breast cancer tumor marker 
tests, but only 11% for EGFR testing in lung cancer. The high values for ERCC1 Stage II 
and BC markers indicate a high level of uncertainty surrounding the key model inputs (e.g. 
the treatment effect hazard ratio). The consequences of making a wrong decision were 
largest for ERCC1 (Stage I: $47,300; Stage II: $22,500) followed by BC markers ($11,700) 
and EGFR ($1,600). These values reflect the average impact on patients in terms of 
morbidity, mortality, and cost when a non-optimal decision is made because of the existing 
uncertainty.
Perceptions of Decision-Makers
Discussions during presentation of the VOI results were primarily focused on clarifying 
technical aspects about the simulation models, the calculation of the affected populations, 
the choice and application of the willingness to pay threshold chosen, and the presentation of 
the VOI results including uncertainty in the VOI estimates.
The ranking of the tests changed from 1) ERCC1, 2) EGFR, and 3) BC markers to 1) 
ERCC1, 2) BC markers, and 3) EGFR. Thus, BC markers were ranked higher relative to 
EGFR compared to the initial prioritization vote. Stakeholders stated this was based on the 
several orders of magnitude difference in VOI between EGFR and BC tumor markers topic 
areas. Specifically, some stakeholders acknowledged that there appeared to be substantially 
more value in studying what they had considered an older, inappropriately used technology 
than they had realized before being presented the VOI analyses. There was recognition that 
if the tumor markers do not provide clinical value, healthcare resources are currently being 
wasted for those who receive testing, and if the markers do provide clinical value, there is a 
significant population of women that could receive a meaningful benefit. Stakeholders also 
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commented that the level of uncertainty for EGFR testing was much lower (11% probability 
of error) compared to BC tumor markers (43% probability of error).
The results of the survey evaluating the VOI process are provided in (Table 1). The majority 
(9/13, 69%) of ESAG members found the VOI analysis to be useful, and approximately half 
(7/13, 53%) stated they changed their priority ratings specifically based on the VOI results. 
All stakeholders reported that they would use results of a VOI analysis in a priority-setting 
process again. In a subsequent follow-up call with stakeholders in which EVSI concepts 
were discussed, several stakeholders noted that this metric would be more appealing to them 
when discussing specific study designs, rather than general research areas.
Discussion
We evaluated the feasibility and perceptions of value of information analysis in a process 
where a diverse group of external stakeholders provided recommendations to SWOG 
regarding priority research areas in cancer genomics. Over the course of approximately 
seven months, we synthesized relevant data, developed decision-analytic models, generated 
VOI results, presented them to the stakeholders, and collected their rankings and opinions.
Implications and Lessons Learned
The results of this pilot study suggest that it is feasible to implement VOI into the research 
prioritization process for a large clinical trials organization; however, VOI is labor-intensive 
and requires staff with specialized training. In addition, we chose a relatively simple 
application of VOI—focusing only on EVPI—in part to make the exercise tractable and 
acceptable to decision makers, but also due to resource and time constraints. The decision 
makers involved in our study appeared to be amenable to this technique, in part, we believe, 
because it was presented simply and across a broad range of topics. In addition, the EVPI 
presents a single dollar value “bottom line” that provides high-level benchmarking of the 
maximum potential benefit of further research on divergent technologies and diseases.
Ultimately, the VOI results appeared to impact some decision makers’ priority ranking of 
the candidate tests. We hypothesize that the large VOI difference (over an order of 
magnitude) between EGFR and BrCA tumor markers was the primary cause of the change 
in prioritization. Although we did not employ a randomized study design to more definitely 
assess the effect of VOI, our findings suggest that VOI did play some role in influencing 
decision makers’ rankings.
Use of Expected Value of Sample Information techniques to inform research prioritization, 
estimate trial size requirements, and incorporate specific research costs may be feasible with 
certain stakeholder groups or types provided that substantial time and resources are applied. 
Approaches to simplify the analysis of the VOI, such as those proposed recently by Meltzer 
et al., will be essential before application of VOI concepts and methods can become 
widespread.(14)
Based on the investigators’ experiences and follow-up interviews with decision makers we 
believe there are two key lessons learned from our VOI research prioritization exercise. 
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First, it is important to involve the stakeholders throughout the entire process from research 
topic selection to model development and analysis such that they are engaged and 
adequately prepared to understand and incorporate the VOI results into the larger research 
prioritization activity. We also believe that it is essential to provide a thorough educational 
component prior to showing the VOI results. Because VOI is a multidimensional concept, 
training allowed decision makers a chance to compare, quantitatively, the factors that most 
influenced the overall result.
The use of VOI analyses to inform research prioritization may be a good investment for 
research organizations and funding agencies given the relatively small cost of such analyses 
compared to the cost of research studies. However, implementing the processes to 
effectively use the information is challenging, and most importantly, time consuming. 
Future efforts likely will need to focus on improving the time efficiency of the process to 
make use of VOI in real-world settings feasible.
Comparison to previous VOI applications
VOI, and EVPI in specific, has been put into practice previously in the U.K. through two 
pilot projects, one for the UK National Coordinating Centre for Health Technology 
Assessment (NCCHTA) and another for the National Institute for Health and Clinical 
Excellence (NICE).(2, 3) The processes and experiences in the UK examples are similar to 
ours with the exception that we used a group of stakeholders with the intent of providing 
recommendations on research priorities in cancer genomics whereas the UK examples 
interacted directly with the research funding organizations that functioned across disease 
areas. The UK funders found the VOI analyses to be interesting, potentially useful, and 
thought that value of information analysis should be considered and developed for future 
prioritization decisions.10
Recently, an AHRQ-funded methods project was undertaken to evaluate model-based EVPI 
calculations for use in research prioritization in the context of a stakeholder process. In 
contrast to our study, the investigators generated per person EVPI estimates as opposed to 
population EVPI, selected cases using convenience sampling as opposed to a landscape 
analysis, and compared stakeholder rankings of research questions (e.g. impact of 
adherence) within comparative effectiveness research areas as opposed to our ranking across 
comparative effectiveness research areas. In accordance with our findings, the investigators 
indicated that the stakeholders were receptive to VOI and that the feasibility of conducting 
VOI within research prioritization processes is contingent upon sufficient time, resources, 
and expertise.(15)
Implications of VOI Results for Cancer Genomic Testing
The VOI analyses indicated that there would be substantial value from additional research 
on ERCC1 testing in early stage NSCLC and BC tumor marker testing in early stage breast 
cancer, but considerable less for EGFR testing to select maintenance treatment in advanced 
NSCLC. These differences highlighted the fact that the existing data on EGFR testing 
provided greater certainty in the association between variants and clinical outcomes (e.g., a 
narrower 95% confidence interval for the treatment effect hazard ratio) relative to the other 
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two interventions. In addition, EGFR testing had the smallest affected population due to its 
more limited indication.(16, 17) Explaining how these factors influenced EVPI made the 
VOI process more transparent to decision makers, and we believe heighted their acceptance 
of the method.
Limitations
This study had a number of limitations that warrant mention. There is the potential for 
selection bias in the composition of the ESAG if stakeholders who agree to participate in a 
research prioritization project in cancer genomics are not representative of stakeholders in 
general. Therefore, in assembling the ESAG, the goal was to ensure active engagement and 
balanced representation among the stakeholder groups. We also used a previous ranking 
against which to compare the post-VOR test rankings, rather than a randomized, controlled 
design, which limits the strength of our conclusions regarding the impact of VOI.
Our stakeholder group was intended to represent the diverse stakeholders involved in cancer 
genomics, and created in light of a guiding principal of CER that such groups should be 
engaged in prioritizing, designing, implementing, and disseminating CER. However, this 
group is clearly different from a funding agency such as NCI or NIH, and further studies, 
particularly in the US, are needed to assess the feasibility of VOI in such settings.
Although we provided the stakeholders with educational materials regarding VOI methods 
and technical aspects underlying the decision-models and VOI calculations, some still 
expressed difficulty understanding the concepts. We attempted to strike a balance between 
adequately preparing the ESAG to understand the VOI models and providing a manageable 
amount of information. Ideally, engaging stakeholders in discussions over VOI should occur 
in a face-to-face setting, with more time for questions and answers about the underlying 
assumptions of the model. In future work, we believe that VOI results or concepts should be 
presented even earlier in the prioritization process.
Finally, several value of information metrics have been introduced and discussed in the 
context of prioritizing comparative effectiveness research including the expected value of 
perfect information, expected value of perfect parameter information, and the expected value 
of sample information.(18–22) We used EVPI, which estimates the upper level dollar value 
of reducing all uncertainty about which strategy is the optimal intervention. It is a pragmatic 
yet limited approach to evaluated VOI. It can provide a useful metric to gauge the general 
state of knowledge as well as the potential benefit of research to patients. If the EVPI is low, 
for example, decision makers can rule out less compelling research opportunities and focus 
resources on areas with greater potential value. However, EVPI has important limitations. A 
very low EVPI may indicate that it is not worth doing a study, but a very high (or even 
moderately high) EVPI does not indicate the opposite. EVSI methods, in contrast, estimate 
the total value of imperfect or limited information from a specific research study, where the 
imperfection arises due to resource constraints and being unable to resolve all forms of 
uncertainty about comparative effectiveness in a pragmatic setting. Ultimately, since 
prioritization of research depends on comparing the expected value of information from a 
pragmatic research study to the cost of performing such a study, EVSI is a more appropriate 
metric to use for the final selection of research projects and also to inform optimal research 
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designs, although significantly greater resources and time are required to conduct EVSI 
calculations. However, there exist two challenges in using such metrics for research 
prioritization in practical settings: 1) the computational burden of EVSI is more complex 
and time consuming than EVPI calculations; and 2) for decision makers, EVSI may be more 
challenging conceptually than EVPI. Assessing the success in communicating EVPI 
information to stakeholders was considered a useful first step before providing EVSI 
information. Moreover, ranking and ruling out research areas (rather than specific studies) 
based on the overall potential value within the research area is the natural step preceding the 
use of EVSI to rank specific study designs. The successful and appropriate implementation 
of VOI in research prioritization processes will require that more transparent and time 
efficient approaches to EVSI be developed.
Conclusion
Prioritizing research topics is becoming increasingly important as research budgets decrease 
and the cost of conducting research continues to rise. This is especially true in comparative 
effectiveness research of cancer genomics, which can require large patient numbers and 
commensurate expenditures. New methods for prioritizing research are needed to ensure that 
our finite research dollars are spent wisely. Applied in concert with professional judgments, 
formal VOI analysis accompanied by sufficient support may help decision makers maximize 
the impact of research portfolios on medical care and human health. Further research on 
VOI approaches and metrics, and explicit integration with existing prioritization processes 
will be essential to achieve the goals of comparative effectiveness research – to provide 
optimal information to stakeholders within existing resource constraints.
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Figure 1. VOI Research Prioritization Process
Figure 1 illustrates the research prioritization process including the development of decision-
analytic models, education of stakeholders about VOI, presentation and discussion the VOI 
results followed by a re-ranking of tests, and the evaluation of the impact and stakeholders’ 
perceptions of the VOI analyses on the research prioritization process.
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Table 2
Value of Information Results












EGFR mutation testing in maintenance 
treatment in advance NSCLC 170,253 12% $1,600 $33
ERCC1 Testing in early stage NSCLC: 
Stage I 234,051 26% $47,300 $2,800
ERCC1 Testing in early stage NSCLC: 
stage II 234,051 42% $22,500 $2,200
Breast Cancer Tumor Marker Testing 416,746 43% $11,700 $2,100
Over 10 years, discounted at 3%;
**
Calculated at $150,000 per QALY willingness to pay
Abbreviations: EGFR, epidermal growth factor receptor; ERCC1, excision repair cross-complementation group 1; BC, breast cancer, NSCLC, non-
small cell lung cancer
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